Second Sight to Discuss Third Quarter 2016 Financial Results on November 2, 2016 Conference Call
October 26 2016 - 8:00AM
Business Wire
Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer,
manufacturer and marketer of implantable visual prosthetics to
provide some useful vision to blind patients, will release its
third quarter 2016 financial results on Wednesday, November 2,
2016, after the close of the U.S. financial markets.
Dr. Robert Greenberg, Chairman, Will McGuire, President and
Chief Executive Officer, and Tom Miller, Chief Financial Officer,
will host a conference call to discuss the results as follows:
Date Wednesday, November
2, 2016 Time 4:30 p.m. EDT Toll free (U.S.) (800) 940-2599
International (212) 231-2913 Webcast (live and replay)
www.secondsight.com under the ‘Investor
Relations’ section.
A replay of the conference call will be available for two weeks
after the call's completion by dialing (800) 633-8284 (U.S.)
or (402) 977-9140 (International). The conference ID for the
replay is 21821062. The archived webcast will be available for 30
days via the aforementioned URL.
About Second Sight
Second Sight's mission is to develop, manufacture and market
innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has
developed and now manufactures and markets the Argus® II Retinal
Prosthesis System. Enrollment has been completed in a feasibility
trial to test the safety and utility of the Argus II in individuals
with Dry Age-Related Macular Degeneration. Second Sight is also
developing the Orion™ I Visual Cortical Prosthesis to restore
some vision to individuals who are blind due to causes other than
preventable or treatable conditions. U.S. Headquarters
are in Sylmar, California, and European Headquarters are
in Lausanne, Switzerland. For more information,
visit www.secondsight.com.
About the Argus® II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation
that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe
to profound outer retinal degeneration such as retinitis pigmentosa
(RP). The Argus II works by converting images captured by a
miniature video camera mounted on the patient's glasses into a
series of small electrical pulses, which are transmitted wirelessly
to an array of electrodes implanted on the surface of the retina.
These pulses are intended to stimulate the retina's remaining
cells, resulting in the perception of patterns of light in the
brain. The patient then learns to interpret these visual patterns,
thereby regaining some useful vision. The system is controlled by
software and is upgradeable, which may provide improved performance
as new algorithms are developed and tested. Therefore current and
future Argus II users may benefit from the continuously improving
technology. The Argus II is the first artificial retina to receive
widespread approval, and is offered at approved centers
in Austria, Canada, France, Germany, Italy, Netherlands, Saudi
Arabia, Spain, Switzerland, Turkey, United
Kingdom and the United States.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161026005504/en/
Investor Relations:Institutional InvestorsIn-Site
Communications, Inc.Lisa Wilson,
212-452-2793Presidentlwilson@insitecony.comorIndividual InvestorsMZ
North AmericaGreg Falesnik, 949-385-6449Senior Vice
Presidentgreg.falensik@mzgroup.us
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024